29 apr: HVIDT I HVIDT - 20 COOL DESIGNKØB
05 maj: FORÅRS (MAVE) FORNEMMELSE - FEM FANTASTISKE OPSKRIFTER
04-05-2011 07:30:26

First Quarter of 2011: Dräger increases net sales and earnings

Drägerwerk AG & Co. KGaA /

First Quarter of 2011: Dräger increases net sales and earnings

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

  • Earnings after income taxes grew 24 percent year-on-year
  • Growth forecast confirmed
  • Stefan Dräger: "Capital structure increases strategic scope of action"

Lübeck - Drägerwerk AG & Co. KGaA's order intake, net sales and earnings increased in the first quarter of 2011. Order intake went up by 11.8 percent (net of currency effects) to EUR 553.6 million year-on-year. Net sales rose by 5.7 percent (net of currency effects) to EUR 500.3 million, with particularly positive developments in the Americas and Asia / Pacific regions. The safety division recorded 9.1 percent growth (net of currency effects), net sales in the medical divisions increased by 3.7 percent. "Given the good first quarter, we are confirming our 2011 growth forecast," said Stefan Dräger, CEO of Drägerwerk Verwaltungs AG.

EBIT margin rose to 8.5 percent

Dräger achieved total Group EBIT of EUR 42.6 million in the first quarter of 2011, an increase of 15.9 percent compared to the prior year's period. The EBIT margin rose from 7.9 percent to 8.5 percent. Higher net sales, favorable exchange rates and positive changes to the product mix contributed to the development. As planned, these amounts were partially used as increased expenses for research and development, marketing and sales as well as IT infrastructure. Earnings after income taxes rose by 24 percent to EUR 23.2 million year-on-year.

Equity ratio went up to 33.1 percent

Dräger Group's equity rose by EUR 11.2 million to EUR 647.8 million in the first three months of 2011, with the equity ratio increasing from 32.2 percent on December 31, 2010, to 33.1 percent. On March 31, 2010, prior to the capital increase, the equity ratio had been at 21.8 percent. "We have more strategic scope of action as our equity is increasing. For this reason, we are aiming to generate an equity ratio of at least 35 percent. We want to be ready for the next slump of the global economy," highlighted Stefan Dräger.

Outlook: Order intake is expected to grow as fast as the overall global economy

Dräger expects its order intake in fiscal year 2011 to grow at least at the pace of global economic growth (IMF April 2011 forecast: +4.4 percent). This is based on the assumption of a stabilizing economy in Europe, continued economic recovery in North America, sustained market growth in developing countries and stable exchange rates. Lifecycle Solutions and Infrastructure Projects in particular are likely to drive expected growth in the lower one-digit percentage range in the medical division and compensate for a possible slowdown in the equipment business. Dräger expects increases in net sales for the safety division in the medium one-digit percentage range. According to the Executive Board, net sales growth in the Group in 2011 is expected to be one to two percentage points down on order intake growth as net sales in 2010 benefited from above-average order intake in the fourth quarter of 2009. Based on planned increases in product development investments, the expansion of the sales organization and improvements to the Group-wide IT infrastructure, Dräger still expects a Group EBIT margin between 7.5 percent and 8.5 percent for fiscal year 2011 (2010: 8.9 percent). In the medium term, the Company aims at growing stronger than the market and achieving an EBIT margin of at least 10 percent.

Key figures for the first three months of 2011 (€ million)

  Q1 2011 Q1 2010 Change Net of currency effects
Order intake 553.6 488.2 +13.4% +11.8%

Medical division

357.1

323.6

+10.4%

+9.2%

Safety division

204.0

172.3

+18.4%

+16.1%

         
Net sales 500.3 465.9 +7.4% +5.7%

Medical division

321.6

306.3

+5.0%

+3.7%

Safety division

185.9

167.0

+11.3%

+9.1%

         
EBIT[1] 42.6 36.8 +15.9%  

Medical division

30.6

40.3

-24.1%

 

Safety division

21.6

12.7

+69.7%

 

         
EBIT margin 8.5% 7.9%    
Earnings after income taxes 23.2 18.7    
EPS[2] preferred share 1.22 1.38    
EPS[2] common share 1.20 1.36    

 

[1] EBIT = Earnings before interest and taxes
[2] EPS = Earnings per share (in €)

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

Contact

Corporate Communications:

Burkard Dillig

Phone: +49 451 882-2185

burkard.dillig@draeger.com

Investor Relations:

Vanina Hoffmann

Phone: +49 451 882-2685

vanina.hoffmann@draeger.com

Drägerwerk AG & Co. KgaA

Moislinger Allee 53-55

23558 Lübeck, Germany

www.draeger.com

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1512151

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
18 okt
OMXC20
Data herunder er lavet på C20 Cap og C20 vægtet til at passe til C20 Cap i 2010 og 2011.   Siden den..
66
16 okt
 
Jeg skriver lige det her indlæg fordi det er 5. gang som investor jeg oplever en af de her lidt stør..
56
16 okt
 
Kære Alle   Jeg takker Jer alle for en god tid her, jeg erkender at have tabt, selvom jeg holdt mig ..
36
17 okt
VWS
Normal 0 21 false false false DA X-NONE X-NONE ..
28
17 okt
I:SP500
  Hvorfor aktiemarkedet ikke er blevet for dyrt   I mit indlæg vedr. aktie- og vækstkrise beskrev je..
21
16 okt
I:SP500
  @bgadk – enig i, at en moderat inflationær politik der holder deflations-spøgelset nede, er præcis..
20
20 okt
VELO
Match, så har jeg set lidt på mine handler og depoter.   Må begynde med at konkludere, at mit handel..
17
20 okt
VELO
Tvivler på at du får ret. Aktieanalytikerne siger allerede før godkendelsen en KORTSIGTET kurs på 2..
17
16 okt
OMXC20
Med reference til mit indlæg af 10.07.2014 emne nummer 280903   Dengang i juli var der uro på marked..
16
16 okt
PNDORA
Til dem som ikke gider trykke over på en anden side: -----------------------------------------------..
14

Høreapparater/Bernstein: Siemens-køb muligt for både GN og WDH

22-10-2014 16:40:02
Det er ikke helt utænkeligt, at en af de to store danske høreapparatproducenter, William Demant Holding og GN Resound, vil kunne absorbere et opkøb af tyske Sie..

Genmab venter royalties fra Arzerra-salg på 27 mio. kr. i Q3

22-10-2014 13:11:49
Genmab regner med at modtage royalties på cirka 27 mio. kr. fra Glaxosmithklines salg af Arzerra i tredje kvartal.Det meddeler Genmab i forbindelse med, at Glax..

Nordea Danmark sværger troskab til Swipp

22-10-2014 11:07:17
Selvom storbanken Nordea nu sætter gang i en storstilet it-offensiv, der skal strømline den pannordiske banks systemer på tværs af landegrænser, så er der ingen..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bavarian/Nordea: Ebola-aftale er veltimet, værdifuld og vigtig
2
Bavarian overrasker med foreløbigt regnskab
3
Bavarian hopper på ebola meddelse
4
Aktier/åbning: Bavarian tordner i vejret
5
Al-Qaeda blæser til kamp mod vestlige olietankere
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. oktober 2014 01:08:37
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141015.1 - EUROWEB3 - 2014-10-23 01:08:37 - 2014-10-23 01:08:37 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x